Top 10 Biotech Exits in Europe Since 2023
Europe’s biotech M&A market has been on a tear. Since 2023, acquirers from MSD to...
Consumer Biotech’s Next Wave: Muscle, Sex, and Psychedelics
GLP-1 drugs have shown the world that blockbuster medicines don’t have to treat disease in...
Top 50 Investors in Biotech in 2026: Europe’s Most Active Life Sciences Funds
Who is writing the cheques that fund Europe’s next generation of medicines? Based on fund...
ASCO 2026: ADC and In Vivo CAR-T Trends in Oncology
What are the biggest trends shaping oncology investment and drug development in 2026? We sat...
How Next-Generation Sequencing is Changing Biopharma Manufacturing
In the strictly regulated world of biopharmaceutical manufacturing, innovation faces a massive hurdle: the industry...
The $6 Billion Excel Illusion: Why Biotech Pipeline Forecasting is Broken (And How to Fix It)
If you sit in a Big Pharma boardroom during a pipeline review, you will inevitably...
The Biotech Equity Gap: Why Curie.Bio is Re-Writing the Founder Playbook
In the high-stakes world of drug discovery, a “brilliant idea” is often described as being...
How Europe could have more Biotech Champions like Argenx
For decades, the narrative of European biotech has been one of “innovation flight”: brilliant science...
Why Antimicrobial Resistance Is Bigger Than Cancer
We’ve been hearing about the Antimicrobial Resistance (AMR) crisis for over a decade. Yet, according...
Biopharma family succession: Bial CEO António Portela’s strategy
In the high-stakes world of pharmaceutical innovation, few stories are as compelling as those of...
